Tamoxifen and Goserelin for Ovarian Cancer
Author Information
Author(s): Hasan J, Ton N, Mullamitha S, Clamp A, McNeilly A, Marshall E, Jayson G C
Primary Institution: Cancer Research UK, Department Medical Oncology, Christie Hospital
Hypothesis
The addition of goserelin to tamoxifen should be associated with greater anticancer activity in ovarian cancer.
Conclusion
Combination endocrine therapy with tamoxifen and goserelin is an active regimen in platinum-resistant ovarian cancer patients.
Supporting Evidence
- The overall clinical benefit rate was 50%, including one complete response and two partial responses.
- The median progression-free interval was 4 months.
- The median overall survival was 13.6 months.
- Treatment was well tolerated with no grade III/IV toxicities reported.
Takeaway
This study tested a combination of two medications, tamoxifen and goserelin, to help women with a tough type of ovarian cancer. It showed that this combination can help some patients live longer without their cancer getting worse.
Methodology
This was an open label, nonrandomised phase II study designed to determine the response rate and progression-free interval in patients with advanced ovarian cancer treated with tamoxifen and goserelin.
Potential Biases
Potential selection bias due to nonrandomised design.
Limitations
The study was nonrandomised and included a small sample size, which may limit the generalizability of the results.
Participant Demographics
The median age of participants was 63 years, with a median of three prior chemotherapy regimens.
Statistical Information
Confidence Interval
95% CI 2.4–9.6 for median progression-free interval; 95% CI 5.5–30.6 for median overall survival.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website